Vesna Sossi Selected Research

Raclopride

1/2021	Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia.
1/2020	Effect of Dopamine D2 Receptor Antagonists on [18F]-FEOBV Binding.
10/2012	Imaging DA release in a rat model of L-DOPA-induced dyskinesias: a longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA.
12/2004	Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
11/2002	Dopamine release in human ventral striatum and expectation of reward.
10/2002	PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vesna Sossi Research Topics

Disease

47	Parkinson Disease (Parkinson's Disease) 01/2022 - 02/2002
9	Parkinsonian Disorders (Parkinsonism) 10/2017 - 12/2005
7	Cognitive Dysfunction 06/2020 - 10/2015
5	Dyskinesias (Dyskinesia) 01/2021 - 12/2004
4	Disease Progression 01/2020 - 08/2004
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019 - 02/2012
3	Bipolar Disorder (Manic Depressive Psychosis) 01/2018 - 05/2002
3	Mania (Manias) 01/2010 - 05/2002
2	Frontotemporal Dementia (Semantic Dementia) 01/2021 - 10/2013
2	Leukoencephalopathies 06/2020 - 10/2019
2	Lacunar Stroke 06/2020 - 10/2019
2	Alzheimer Disease (Alzheimer's Disease) 06/2020 - 10/2019
2	Transient Ischemic Attack 06/2020 - 10/2019
2	Body Weight (Weight, Body) 01/2020 - 05/2012
2	Neoplasms (Cancer) 03/2018 - 01/2017
1	Neuroinflammatory Diseases 01/2019
1	Major Depressive Disorder (Major Depressive Disorders) 01/2018
1	Intellectual Disability (Idiocy) 10/2017
1	Triple Negative Breast Neoplasms 01/2017
1	Breast Neoplasms (Breast Cancer) 01/2017
1	Hypoxia (Hypoxemia) 01/2016
1	Mixed Dementias 10/2015
1	Dementia (Dementias) 10/2013
1	Substance-Related Disorders (Drug Abuse) 10/2012
1	Secondary Parkinson Disease (Secondary Parkinsonism) 04/2012
1	Treatment-Resistant Depressive Disorder 06/2010
1	Huntington Disease (Huntington's Disease) 08/2005

Drug/Important Bio-Agent (IBA)

28	Dopamine (Intropin)FDA LinkGeneric 01/2022 - 02/2002
13	Levodopa (L Dopa)FDA LinkGeneric 01/2021 - 05/2002
9	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 01/2022 - 11/2007
6	RacloprideIBA 01/2021 - 10/2002
5	Oxidopamine (6 Hydroxydopamine)IBA 05/2012 - 09/2006
4	Biomarkers (Surrogate Marker)IBA 12/2019 - 11/2011
4	Amyloid (Amyloid Fibrils)IBA 01/2019 - 10/2015
3	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 10/2013
3	Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA 01/2021 - 11/2007
3	Methylphenidate (Ritalin)FDA LinkGeneric 01/2021 - 07/2006
3	Dihydroxyphenylalanine (Dopa)IBA 01/2019 - 05/2002
3	Phosphotransferases (Kinase)IBA 01/2019 - 12/2005
3	Leucine (L-Leucine)FDA Link 01/2019 - 12/2005
3	fluorodopa F 18IBA 01/2017 - 02/2002
2	alpha-SynucleinIBA 01/2022 - 01/2017
2	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 01/2021 - 01/2017
2	dihydrotetrabenazineIBA 01/2021 - 01/2020
2	benzonitrileIBA 01/2021 - 01/2018
2	florbetapirIBA 06/2020 - 10/2019
2	Cholinergic Agents (Cholinergics)IBA 01/2020 - 01/2018
2	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 01/2019 - 01/2019
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2019 - 10/2012
2	Antidepressive Agents (Antidepressants)IBA 01/2018 - 06/2010
2	Proteins (Proteins, Gene)FDA Link 07/2017 - 01/2015
2	Serotonin (5 Hydroxytryptamine)IBA 01/2017 - 01/2010
2	SynucleinsIBA 01/2015 - 04/2012
2	setoperoneIBA 06/2010 - 01/2010
2	Pharmaceutical PreparationsIBA 06/2010 - 01/2010
2	Antipsychotic Agents (Antipsychotics)IBA 10/2002 - 05/2002
2	Valproic Acid (Depakote)FDA LinkGeneric 10/2002 - 05/2002
1	Haloperidol (Haldol)FDA LinkGeneric 01/2020
1	Dihydrotachysterol (AT 10)IBA 01/2019
1	3- amino- 4- (2- dimethylaminomethylphenylsulfanyl)benzonitrileIBA 01/2018
1	O-methyl reboxetineIBA 01/2018
1	Quetiapine Fumarate (Seroquel)FDA Link 01/2018
1	AcetylcholinesteraseIBA 01/2018
1	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 01/2018
1	dextran-2-hydroxy-3-mercaptopropyl ether (C 79)IBA 10/2017
1	Messenger RNA (mRNA)IBA 01/2017
1	5-fluoroaminosuberic acidIBA 01/2017
1	Amyloid beta-PeptidesIBA 01/2017
1	AcidsIBA 01/2017
1	ProgranulinsIBA 10/2013
1	Phospholipases A2 (Phospholipase A2)IBA 11/2012
1	N-Methyl-3,4-methylenedioxyamphetamine (MDMA)IBA 10/2012
1	Amphetamine (Amfetamine)FDA LinkGeneric 10/2012
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 04/2012
1	5-HT2 Serotonin ReceptorsIBA 01/2010
1	levodopa drug combination carbidopa (Nakom)FDA LinkGeneric 12/2004

Therapy/Procedure

7	Therapeutics 01/2020 - 06/2010
4	Denervation 01/2020 - 04/2006
2	Transplantation 08/2005 - 09/2003
1	Radiotherapy 03/2018
1	Deep Brain Stimulation 01/2017
1	Oral Administration 12/2004
1	Aftercare (After-Treatment) 05/2002